Table 3 includes clinically significant drug interactions affecting other drugs.
CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions | |
Clinical Impact | Ritlecitinib is a CYP3A inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP3A substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions of these substrates. |
Intervention | Consider additional monitoring and dosage adjustment in accordance with approved product labeling of CYP3A substrates where small concentration changes may lead to serious adverse reactions when used with LITFULO. |
CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions | |
Clinical Impact | Ritlecitinib is a CYP1A2 inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP1A2 substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions of these substrates. |
Intervention | Consider additional monitoring and dosage adjustment in accordance with the approved product labeling of CYP1A2 substrates where small concentration changes may lead to serious adverse reactions when used concomitantly with LITFULO. |
Table 4 includes clinically significant drug interactions affecting LITFULO.
CYP3A Inducers | |
Clinical Impact | Concomitant use of strong CYP3A inducer (e.g., rifampin) may decrease AUC and Cmax of ritlecitinib [see Clinical Pharmacology (12.3)], which may result in loss of or reduced clinical response. |
Intervention | Coadministration with strong inducers of CYP3A is not recommended. |
Table 3 includes clinically significant drug interactions affecting other drugs.
CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions | |
Clinical Impact | Ritlecitinib is a CYP3A inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP3A substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions of these substrates. |
Intervention | Consider additional monitoring and dosage adjustment in accordance with approved product labeling of CYP3A substrates where small concentration changes may lead to serious adverse reactions when used with LITFULO. |
CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions | |
Clinical Impact | Ritlecitinib is a CYP1A2 inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP1A2 substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions of these substrates. |
Intervention | Consider additional monitoring and dosage adjustment in accordance with the approved product labeling of CYP1A2 substrates where small concentration changes may lead to serious adverse reactions when used concomitantly with LITFULO. |
Table 4 includes clinically significant drug interactions affecting LITFULO.
CYP3A Inducers | |
Clinical Impact | Concomitant use of strong CYP3A inducer (e.g., rifampin) may decrease AUC and Cmax of ritlecitinib [see Clinical Pharmacology (12.3)], which may result in loss of or reduced clinical response. |
Intervention | Coadministration with strong inducers of CYP3A is not recommended. |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.